[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Yohimbine is combined with Antipyrine.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Yohimbine.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Yohimbine.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Yohimbine.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Yohimbine is combined with Sulthiame.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Yohimbine is combined with Azapropazone.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Yohimbine.]
[N05CD07, temazepam, The therapeutic efficacy of Temazepam can be increased when used in combination with Yohimbine.]
[R03CC03, terbutaline, The risk or severity of hypertension can be increased when Terbutaline is combined with Yohimbine.]
[N07XX06, tetrabenazine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Yohimbine is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Yohimbine.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Yohimbine.]
[L04AX02, thalidomide, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Yohimbine.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Yohimbine.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Yohimbine.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Thioproperazine.]
[N05AC02, thioridazine, The metabolism of Yohimbine can be decreased when combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Yohimbine is combined with Thiothixene.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Yohimbine.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Yohimbine is combined with Moxisylyte.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Yohimbine is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Yohimbine can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Tilidine.]
[S01ED01, timolol, Yohimbine may decrease the antihypertensive activities of Timolol.]
[M02AX02, tolazoline, Yohimbine may decrease the antihypertensive activities of Tolazoline.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Yohimbine.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Yohimbine is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Yohimbine is combined with Tramadol.]
[N06AF04, tranylcypromine, The therapeutic efficacy of Tranylcypromine can be increased when used in combination with Yohimbine.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Yohimbine.]
[N05CD05, triazolam, The therapeutic efficacy of Triazolam can be increased when used in combination with Yohimbine.]
[C03AA06, trichlormethiazide, Yohimbine may decrease the antihypertensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Yohimbine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Yohimbine is combined with Trifluperidol.]
[N05AA05, triflupromazine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Alimemazine is combined with Yohimbine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Yohimbine.]
[C02BA01, trimethaphan, Yohimbine may decrease the antihypertensive activities of Trimethaphan.]
[N06AA06, trimipramine, The serum concentration of Yohimbine can be increased when it is combined with Trimipramine.]
[R06AC04, tripelennamine, The metabolism of Yohimbine can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Yohimbine.]
[A03BB01, butylscopolamine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Yohimbine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Yohimbine can be decreased when combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Yohimbine.]
[C09CA09, azilsartan medoxomil, Yohimbine may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Yohimbine.]
[L02BX03, abiraterone, The metabolism of Yohimbine can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Yohimbine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Yohimbine can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Yohimbine can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Yohimbine can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Ezogabine.]
[R03AC18, indacaterol, The risk or severity of hypertension can be increased when Yohimbine is combined with Indacaterol.]
[C08DA01, verapamil, The metabolism of Yohimbine can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Yohimbine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Yohimbine can be decreased when combined with Vinblastine.]
[C04AX07, vincamine, Yohimbine may decrease the antihypertensive activities of Vincamine.]
[B01AA03, warfarin, The risk or severity of adverse effects can be increased when Yohimbine is combined with Warfarin.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Yohimbine is combined with Xenon.]
[C03BA10, xipamide, Yohimbine may decrease the antihypertensive activities of Xipamide.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Yohimbine is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Yohimbine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Yohimbine.]
[L01EC01, vemurafenib, The metabolism of Yohimbine can be decreased when combined with Vemurafenib.]
[L01ED01, crizotinib, The metabolism of Yohimbine can be decreased when combined with Crizotinib.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Yohimbine is combined with Ziprasidone.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Yohimbine.]
[G04BD07, tolterodine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, Yohimbine may decrease the antihypertensive activities of Atenolol.]
[J02AC03, voriconazole, The metabolism of Yohimbine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Yohimbine is combined with Atracurium.]
[S01FA01, atropine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[G04BE10, avanafil, Yohimbine may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Yohimbine.]
[A08AA11, lorcaserin, The metabolism of Yohimbine can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Yohimbine can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Yohimbine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Yohimbine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Yohimbine can be decreased when it is combined with Enzalutamide.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Yohimbine is combined with Octopamine.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Yohimbine is combined with Barbital.]
[J05AE04, nelfinavir, The metabolism of Yohimbine can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Yohimbine.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Rasagiline is combined with Yohimbine.]
[C08CA13, lercanidipine, Yohimbine may decrease the antihypertensive activities of Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Yohimbine is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Yohimbine.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Yohimbine.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Yohimbine.]
[R06AC06, thonzylamine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Yohimbine can be decreased when combined with Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Yohimbine is combined with Diethyl ether.]
[G04BE03, sildenafil, The metabolism of Yohimbine can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Yohimbine.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Yohimbine.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Yohimbine can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Yohimbine may decrease the antihypertensive activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Yohimbine is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Yohimbine can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Yohimbine is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Yohimbine is combined with Benperidol.]
[A06AX06, tegaserod, The metabolism of Yohimbine can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Benzocaine is combined with Yohimbine.]
[M01AH01, celecoxib, The metabolism of Yohimbine can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Yohimbine.]
[L04AA18, everolimus, The metabolism of Yohimbine can be decreased when combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Yohimbine can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Yohimbine is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Yohimbine is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Yohimbine is combined with Levomilnacipran.]
[C08EA02, bepridil, The metabolism of Yohimbine can be decreased when combined with Bepridil.]
[C02KX05, riociguat, Yohimbine may decrease the antihypertensive activities of Riociguat.]
[C02KX04, macitentan, Yohimbine may decrease the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Yohimbine.]
[N06AX26, vortioxetine, The therapeutic efficacy of Vortioxetine can be increased when used in combination with Yohimbine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Yohimbine can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Yohimbine.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Yohimbine.]
[C01CA27, droxidopa, Yohimbine may decrease the hypertensive activities of Droxidopa.]
[C07AB04, acebutolol, The metabolism of Yohimbine can be decreased when combined with Acebutolol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Yohimbine is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Yohimbine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Yohimbine can be increased when combined with Apremilast.]
[S01ED02, betaxolol, Yohimbine may decrease the antihypertensive activities of Betaxolol.]
[C02CC01, bethanidine, Yohimbine may decrease the antihypertensive activities of Bethanidine.]
[L04AC11, siltuximab, The metabolism of Yohimbine can be increased when combined with Siltuximab.]
[A03BA03, hyoscyamine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of adverse effects can be increased when Yohimbine is combined with Acenocoumarol.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Yohimbine is combined with Alfaxalone.]
[R03AC19, olodaterol, The risk or severity of hypertension can be increased when Yohimbine is combined with Olodaterol.]
[D11AA01, glycopyrronium, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Yohimbine can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Yohimbine can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Acepromazine.]
[N04AA02, biperiden, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Yohimbine.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Yohimbine.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Yohimbine is combined with Dicoumarol.]
[N06AX11, mirtazapine, Yohimbine may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Yohimbine can be increased when combined with Secukinumab.]
[L01XH03, panobinostat, The metabolism of Yohimbine can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Yohimbine can be decreased when combined with Acetaminophen.]
[A03AA09, difemerine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Yohimbine is combined with Tioclomarol.]
[J05AP06, asunaprevir, The metabolism of Yohimbine can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Yohimbine is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Yohimbine is combined with Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Yohimbine can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Yohimbine is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Yohimbine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Yohimbine is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Yohimbine.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Yohimbine.]
[A02BC03, lansoprazole, The metabolism of Yohimbine can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Yohimbine.]
[J02AC05, isavuconazole, The metabolism of Yohimbine can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, Yohimbine may decrease the antihypertensive activities of Selexipag.]
[G04CA01, alfuzosin, Yohimbine may increase the hypotensive activities of Alfuzosin.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Yohimbine.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Yohimbine is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Yohimbine is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Yohimbine can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The therapeutic efficacy of Bromazepam can be increased when used in combination with Yohimbine.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Yohimbine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Yohimbine.]
[N06AA19, amineptin, The serum concentration of Yohimbine can be increased when it is combined with Amineptine.]
[C08CA01, amlodipine, Yohimbine may decrease the antihypertensive activities of Amlodipine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Yohimbine is combined with Aniracetam.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Yohimbine.]
[C07AA19, bupranolol, Yohimbine may decrease the antihypertensive activities of Bupranolol.]
[N07BC01, buprenorphine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Yohimbine.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Yohimbine.]
[S01GX07, azelastine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Yohimbine can be decreased when combined with Rucaparib.]
[L01EF02, ribociclib, The metabolism of Yohimbine can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Balsalazide is combined with Yohimbine.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Yohimbine is combined with Bambuterol.]
[N07XX16, deutetrabenazine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Yohimbine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Yohimbine is combined with Beclamide.]
[C09AA07, benazepril, Yohimbine may decrease the antihypertensive activities of Benazepril.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Yohimbine.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Yohimbine.]
[J05AE09, tipranavir, The metabolism of Yohimbine can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Yohimbine.]
[L04AB02, infliximab, The metabolism of Yohimbine can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Yohimbine can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Yohimbine is combined with Safinamide.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Yohimbine.]
[C07AB07, bisoprolol, Yohimbine may decrease the antihypertensive activities of Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Bitolterol is combined with Yohimbine.]
[J05AG03, efavirenz, The metabolism of Yohimbine can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Yohimbine.]
[N04AA11, bornaprine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Yohimbine is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Yohimbine is combined with Brotizolam.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Yohimbine is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Yohimbine is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Yohimbine.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Yohimbine.]
[N06AA15, butriptyline, The therapeutic efficacy of Butriptyline can be increased when used in combination with Yohimbine.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Yohimbine is combined with Vinylbital.]
[C09AA01, captopril, Yohimbine may decrease the antihypertensive activities of Captopril.]
[L02BB05, apalutamide, The metabolism of Yohimbine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Yohimbine can be increased when combined with Carbamazepine.]
[A03AA03, camylofine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Yohimbine.]
[C07AG02, carvedilol, Yohimbine may decrease the antihypertensive activities of Carvedilol.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Yohimbine.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Yohimbine.]
[C07AB08, celiprolol, Yohimbine may decrease the antihypertensive activities of Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Yohimbine.]
[L01XX62, ivosidenib, The metabolism of Yohimbine can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Yohimbine.]
[N03AX17, stiripentol, The metabolism of Yohimbine can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Yohimbine.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Yohimbine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Yohimbine is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Yohimbine.]
[R06AA06, chlorphenoxamine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Yohimbine is combined with Lornoxicam.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Yohimbine.]
[R03BB08, revefenacin, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L04AA39, emapalumab, The metabolism of Yohimbine can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The therapeutic efficacy of Yohimbine can be decreased when used in combination with Gilteritinib.]
[C09AA08, cilazapril, Yohimbine may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The metabolism of Yohimbine can be decreased when combined with Cilostazol.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Yohimbine is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Yohimbine can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Yohimbine.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Yohimbine is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Yohimbine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Yohimbine.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Yohimbine is combined with Brexanolone.]
[N05BA09, clobazam, The therapeutic efficacy of Clobazam can be increased when used in combination with Yohimbine.]
[N05BA22, cloxazolam, The therapeutic efficacy of Cloxazolam can be increased when used in combination with Yohimbine.]
[C09CA06, candesartan, Yohimbine may decrease the antihypertensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Yohimbine can be increased when combined with Etanercept.]
[N05AA06, cyamemazine, The therapeutic efficacy of Cyamemazine can be increased when used in combination with Yohimbine.]
[C03BX03, cicletanine, Yohimbine may decrease the antihypertensive activities of Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Yohimbine.]
[L01EJ02, fedratinib, The metabolism of Yohimbine can be decreased when combined with Fedratinib.]
[N07XX11, pitolisant, The serum concentration of Yohimbine can be decreased when it is combined with Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Yohimbine.]
[C03AA09, cyclothiazide, Yohimbine may decrease the antihypertensive activities of Cyclothiazide.]
[S01AA13, fusidic acid, The metabolism of Yohimbine can be decreased when combined with Fusidic acid.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Yohimbine.]
[N03AX25, cenobamate, The serum concentration of Yohimbine can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Yohimbine can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Yohimbine.]
[R06AB02, dexchlorpheniramine, The metabolism of Yohimbine can be decreased when combined with Dexchlorpheniramine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Dezocine is combined with Yohimbine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Yohimbine is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Yohimbine is combined with Lumateperone.]
[M01AX21, diacetylrhein, The metabolism of Yohimbine can be decreased when combined with Diacerein.]
[H02CA02, osilodrostat, The metabolism of Yohimbine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Yohimbine can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Yohimbine.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Dutasteride is combined with Yohimbine.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Yohimbine is combined with Dichloralphenazone.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Yohimbine is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Yohimbine.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Yohimbine.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be decreased when combined with Yohimbine.]
[C01BD07, dronedarone, The metabolism of Yohimbine can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Yohimbine is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The therapeutic efficacy of Chlordiazepoxide can be increased when used in combination with Yohimbine.]
[C02AA06, methoserpidine, Yohimbine may decrease the antihypertensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Yohimbine.]
[A03AA08, dihexyverine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Yohimbine.]
[G04BD09, trospium, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Yohimbine is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Yohimbine is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Yohimbine is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Yohimbine is combined with Clomethiazole.]
[M03BB02, chlormezanone, The therapeutic efficacy of Chlormezanone can be increased when used in combination with Yohimbine.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Yohimbine.]
[C08CA17, levamlodipine, Yohimbine may decrease the antihypertensive activities of Levamlodipine.]
[P01BB01, proguanil, The metabolism of Yohimbine can be decreased when combined with Proguanil.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Yohimbine is combined with Remimazolam.]
[N07XX04, sodium oxybate, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[L04AC19, satralizumab, The serum concentration of Yohimbine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Yohimbine is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Yohimbine can be decreased when combined with Chloroquine.]
[C03AA04, chlorothiazide, Yohimbine may decrease the antihypertensive activities of Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Yohimbine.]
[N05AA01, chlorpromazine, The metabolism of Yohimbine can be decreased when combined with Chlorpromazine.]
[N05AF03, chlorprothixene, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Yohimbine may decrease the antihypertensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Yohimbine.]
[A11CC05, cholecalciferol, The metabolism of Yohimbine can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, The therapeutic efficacy of Etifoxine can be increased when used in combination with Yohimbine.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Yohimbine is combined with Ethenzamide.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The therapeutic efficacy of Ethyl loflazepate can be increased when used in combination with Yohimbine.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Yohimbine.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Yohimbine is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Yohimbine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Yohimbine can be decreased when combined with Lonafarnib.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Yohimbine is combined with Naxitamab.]
[P03AX07, abametapir, The serum concentration of Yohimbine can be increased when it is combined with Abametapir.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Yohimbine is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Yohimbine.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Yohimbine is combined with Fenbufen.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Yohimbine.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Yohimbine is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Finasteride is combined with Yohimbine.]
[R03CC15, formoterol, The risk or severity of hypertension can be increased when Formoterol is combined with Yohimbine.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Yohimbine is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Yohimbine can be decreased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Yohimbine may decrease the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Yohimbine can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Yohimbine.]
[N07CA02, cinnarizine, The metabolism of Yohimbine can be decreased when combined with Cinnarizine.]
[L01XX73, sotorasib, The serum concentration of Yohimbine can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Yohimbine can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Yohimbine is combined with Citalopram.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Yohimbine.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Yohimbine.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Mefenamic acid is combined with Yohimbine.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Yohimbine is combined with Clenbuterol.]
[N06AX25, St. John's wort extract, The metabolism of Yohimbine can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Yohimbine.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Yohimbine.]
[N06AA04, clomipramine, The serum concentration of Yohimbine can be increased when it is combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Yohimbine.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Yohimbine.]
[C01EB24, mavacamten, The serum concentration of Yohimbine can be decreased when it is combined with Mavacamten.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Clothiapine.]
[N05BA21, clotiazepam, The therapeutic efficacy of Clotiazepam can be increased when used in combination with Yohimbine.]
[A04AA01, ondansetron, The therapeutic efficacy of Ondansetron can be increased when used in combination with Yohimbine.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Yohimbine.]
[N05AH02, clozapine, The metabolism of Yohimbine can be decreased when combined with Clozapine.]
[N05BA13, halazepam, The therapeutic efficacy of Halazepam can be increased when used in combination with Yohimbine.]
[H01AC08, somatrogon, The metabolism of Yohimbine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Yohimbine may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Yohimbine can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Yohimbine is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Yohimbine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Yohimbine.]
[A03AB10, hexocyclium, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Yohimbine.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Yohimbine is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Yohimbine is combined with Ifenprodil.]
[A10BX03, nateglinide, The metabolism of Yohimbine can be decreased when combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Yohimbine is combined with Imidazole salicylate.]
[J01FA15, telithromycin, The metabolism of Yohimbine can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Yohimbine.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Yohimbine is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Yohimbine.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Yohimbine.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Yohimbine is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Yohimbine.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Yohimbine is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Yohimbine can be decreased when combined with Itraconazole.]
[N05BA10, ketazolam, The therapeutic efficacy of Ketazolam can be increased when used in combination with Yohimbine.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Yohimbine is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Yohimbine can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Yohimbine can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Yohimbine may decrease the antihypertensive activities of Lacidipine.]
[N03AX09, lamotrigine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Yohimbine can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Yohimbine is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Yohimbine is combined with Lormetazepam.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Yohimbine is combined with Loxoprofen.]
[C09AA03, lisinopril, Yohimbine may decrease the antihypertensive activities of Lisinopril.]
[C08CA11, manidipine, The metabolism of Yohimbine can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Medifoxamine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Yohimbine is combined with Mefenorex.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Yohimbine.]
[R06AD07, mequitazine, The metabolism of Yohimbine can be decreased when combined with Mequitazine.]
[N04AA03, methixene, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Yohimbine can be decreased when used in combination with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Yohimbine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Yohimbine is combined with Cyclobarbital.]
[C03DA04, eplerenone, Yohimbine may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Yohimbine is combined with Melperone.]
[C03AA07, cyclopenthiazide, Yohimbine may decrease the antihypertensive activities of Cyclopenthiazide.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Yohimbine.]
[S01XA18, cyclosporine, The metabolism of Yohimbine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Moclobemide is combined with Yohimbine.]
[R06AX02, cyproheptadine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, Yohimbine may decrease the antihypertensive activities of Moexipril.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Yohimbine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Yohimbine is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Yohimbine can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, Yohimbine may decrease the antihypertensive activities of Moxonidine.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Yohimbine is combined with Etoricoxib.]
[G03XA01, danazol, The metabolism of Yohimbine can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Yohimbine.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Yohimbine is combined with Deanol.]
[C02CC04, debrisoquin, Yohimbine may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Yohimbine.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Yohimbine.]
[N05BA16, nordazepam, The therapeutic efficacy of Nordazepam can be increased when used in combination with Yohimbine.]
[C07AB12, nebivolol, Yohimbine may decrease the antihypertensive activities of Nebivolol.]
[N06AX06, nefazodone, The metabolism of Yohimbine can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Niaprazine.]
[C01DX16, nicorandil, Yohimbine may decrease the antihypertensive activities of Nicorandil.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Yohimbine.]
[C01CA23, theodrenaline, Yohimbine may decrease the hypertensive activities of Theodrenaline.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Yohimbine.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Yohimbine is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Yohimbine is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Yohimbine is combined with Escitalopram.]
[G04BD08, solifenacin, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Olsalazine is combined with Yohimbine.]
[N06AA01, desipramine, The serum concentration of Yohimbine can be increased when it is combined with Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Yohimbine.]
[C09XA02, aliskiren, Yohimbine may decrease the antihypertensive activities of Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Oxaprozin is combined with Yohimbine.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Yohimbine.]
[S03BA01, dexamethasone, The metabolism of Yohimbine can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Yohimbine is combined with Oxiracetam.]
[N04AA08, dexetimide, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Dexfenfluramine is combined with Yohimbine.]
[A03AA01, oxyphencyclimine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Yohimbine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Yohimbine can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Yohimbine can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Yohimbine.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Yohimbine.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Yohimbine is combined with Dextromoramide.]
[N06AB05, paroxetine, The metabolism of Yohimbine can be decreased when combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Yohimbine is combined with Diamorphine.]
[N05BA01, diazepam, The therapeutic efficacy of Diazepam can be increased when used in combination with Yohimbine.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Yohimbine.]
[V03AH01, diazoxide, Yohimbine may decrease the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Yohimbine.]
[N06AA08, dibenzepin, The serum concentration of Yohimbine can be increased when it is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Yohimbine.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Diclofenac is combined with Yohimbine.]
[A03AA07, dicyclomine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[C02DG01, pinacidil, Yohimbine may decrease the antihypertensive activities of Pinacidil.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Yohimbine is combined with Pipamperone.]
[A03AB14, pipenzolate, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Yohimbine.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Pirbuterol is combined with Yohimbine.]
[A08AA03, diethylpropion, The therapeutic efficacy of Yohimbine can be decreased when used in combination with Diethylpropion.]
[C08CA03, isradipine, The metabolism of Yohimbine can be decreased when combined with Isradipine.]
[A03AB11, poldine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Diflunisal is combined with Yohimbine.]
[C02DB01, dihydralazine, Yohimbine may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Yohimbine is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Yohimbine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Yohimbine.]
[J05AE08, atazanavir, The metabolism of Yohimbine can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Yohimbine may decrease the antihypertensive activities of Treprostinil.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Yohimbine can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Yohimbine.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Yohimbine is combined with Pridinol.]
[R06AB03, dimethindene, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Procaterol is combined with Yohimbine.]
[M02AX03, dimethyl sulfoxide, The metabolism of Yohimbine can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Yohimbine.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Yohimbine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Yohimbine is combined with Proglumetacin.]
[R06AA02, diphenhydramine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Yohimbine.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Yohimbine is combined with Quazepam.]
[C09AA06, quinapril, Yohimbine may decrease the antihypertensive activities of Quinapril.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Yohimbine is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The serum concentration of Yohimbine can be increased when it is combined with Quinupramine.]
[A03FA02, cisapride, The metabolism of Yohimbine can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Yohimbine may decrease the antihypertensive activities of Ramipril.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Yohimbine.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Yohimbine is combined with Reproterol.]
[C01BA03, disopyramide, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Yohimbine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Yohimbine can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Yohimbine.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Yohimbine.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Yohimbine.]
[A04AD12, aprepitant, The metabolism of Yohimbine can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The metabolism of Yohimbine can be decreased when combined with Bortezomib.]
[G04BE08, tadalafil, Yohimbine may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Yohimbine.]
[C02KX02, ambrisentan, Yohimbine may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Yohimbine can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Yohimbine is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypertension can be increased when Salmeterol is combined with Yohimbine.]
[C01CA07, dobutamine, The risk or severity of hypertension can be increased when Dobutamine is combined with Yohimbine.]
[A03FA03, domperidone, The metabolism of Yohimbine can be decreased when combined with Domperidone.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Dopamine is combined with Yohimbine.]
[N06AA16, dothiepin, The serum concentration of Yohimbine can be increased when it is combined with Dosulepin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Yohimbine.]
[N06AA12, doxepin, The serum concentration of Yohimbine can be increased when it is combined with Doxepin.]
[L01DB01, doxorubicin, The metabolism of Yohimbine can be decreased when combined with Doxorubicin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Yohimbine.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Yohimbine is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Yohimbine.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Yohimbine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Yohimbine can be decreased when combined with Simvastatin.]
[C09AA11, spirapril, Yohimbine may decrease the antihypertensive activities of Spirapril.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Yohimbine is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Yohimbine.]
[C07AB13, talinolol, Yohimbine may decrease the antihypertensive activities of Talinolol.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Yohimbine.]
[G04CA03, terazosin, Yohimbine may decrease the antihypertensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Yohimbine can be decreased when combined with Terbinafine.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Yohimbine.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Yohimbine is combined with Tetryzoline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Yohimbine is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Yohimbine is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Yohimbine is combined with Thiopropazate.]
[G04BD01, emepronium, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The serum concentration of Yohimbine can be increased when it is combined with Tianeptine.]
[C09AA02, enalapril, Yohimbine may decrease the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, The therapeutic efficacy of Tofisopam can be increased when used in combination with Yohimbine.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Yohimbine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Yohimbine is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Yohimbine.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Yohimbine.]
[C03CA04, torsemide, Yohimbine may decrease the antihypertensive activities of Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Yohimbine is combined with Tramazoline.]
[C09AA10, trandolapril, Yohimbine may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, The therapeutic efficacy of Loprazolam can be increased when used in combination with Yohimbine.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Yohimbine is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Yohimbine is combined with Triclofos.]
[A03AB08, tridihexethyl, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Yohimbine.]
[N04AA12, tropatepine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Yohimbine is combined with Tulobuterol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Yohimbine.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Yohimbine is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Yohimbine is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Yohimbine can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, Yohimbine may decrease the hypertensive activities of Ephedrine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Yohimbine.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Yohimbine is combined with Venlafaxine.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Yohimbine is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Yohimbine is combined with Xylometazoline.]
[C08CA12, mepirodipine, The metabolism of Yohimbine can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, Yohimbine may decrease the hypertensive activities of Epinephrine.]
[C09AA15, zofenopril, Yohimbine may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Yohimbine is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Yohimbine.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Yohimbine is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Yohimbine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Yohimbine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Yohimbine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Yohimbine.]
[N02CA02, ergotamine, The metabolism of Yohimbine can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Yohimbine can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The therapeutic efficacy of Estazolam can be increased when used in combination with Yohimbine.]
[H05BX01, cinacalcet, The metabolism of Yohimbine can be decreased when combined with Cinacalcet.]
[J04AK02, ethambutol, The metabolism of Yohimbine can be decreased when combined with Ethambutol.]
[C10AA04, fluvastatin, The metabolism of Yohimbine can be decreased when combined with Fluvastatin.]
[C01CA15, gepefrine, The therapeutic efficacy of Yohimbine can be decreased when used in combination with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Yohimbine.]
[N04AA05, profenamine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Yohimbine.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Yohimbine.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Yohimbine.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Yohimbine is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Yohimbine.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Yohimbine is combined with Sertindole.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Yohimbine.]
[R06AX12, terfenadine, The metabolism of Yohimbine can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Yohimbine can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The therapeutic efficacy of Fluvoxamine can be increased when used in combination with Yohimbine.]
[C01BC08, encainide, The metabolism of Yohimbine can be decreased when combined with Encainide.]
[C08CA02, felodipine, The metabolism of Yohimbine can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, The therapeutic efficacy of Fenfluramine can be decreased when used in combination with Yohimbine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Yohimbine.]
[R03CC04, fenoterol, The risk or severity of hypertension can be increased when Fenoterol is combined with Yohimbine.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Yohimbine.]
[R03CC02, albuterol, The risk or severity of hypertension can be increased when Salbutamol is combined with Yohimbine.]
[N07AX03, cevimeline, The metabolism of Yohimbine can be decreased when combined with Cevimeline.]
[G04BD02, flavoxate, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Yohimbine.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Yohimbine is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Yohimbine can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Flunarizine.]
[N05CD03, flunitrazepam, The therapeutic efficacy of Flunitrazepam can be increased when used in combination with Yohimbine.]
[N06AA14, melitracen, The serum concentration of Yohimbine can be increased when it is combined with Melitracen.]
[V03AZ01, ethanol, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[N06AB03, fluoxetine, The serum concentration of Yohimbine can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Yohimbine.]
[N05CD01, flurazepam, The therapeutic efficacy of Flurazepam can be increased when used in combination with Yohimbine.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Yohimbine.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Yohimbine is combined with Fluspirilene.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Yohimbine is combined with Adrafinil.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Yohimbine is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Yohimbine.]
[J05AE10, darunavir, The metabolism of Yohimbine can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Yohimbine may decrease the antihypertensive activities of Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Yohimbine is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Yohimbine is combined with Amisulpride.]
[N06DA04, galantamine, The metabolism of Yohimbine can be decreased when combined with Galantamine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Gallamine.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Yohimbine is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Yohimbine is combined with Bifemelane.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Yohimbine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Yohimbine is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Yohimbine.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Yohimbine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Yohimbine is combined with Glutethimide.]
[C05AE01, nitroglycerin, Yohimbine may decrease the antihypertensive activities of Nitroglycerin.]
[C02CA04, doxazosin, Yohimbine may decrease the antihypertensive activities of Doxazosin.]
[C07AB09, esmolol, Yohimbine may decrease the antihypertensive activities of Esmolol.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Yohimbine is combined with Fluindione.]
[C09AA09, fosinopril, Yohimbine may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Yohimbine may decrease the antihypertensive activities of Guanethidine.]
[P01BX01, halofantrine, The metabolism of Yohimbine can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Yohimbine.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Yohimbine.]
[N05AH04, quetiapine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Yohimbine is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Yohimbine is combined with Allobarbital.]
[C09CA01, losartan, Yohimbine may decrease the antihypertensive activities of Losartan.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Yohimbine.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Yohimbine.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Yohimbine is combined with Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Yohimbine can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Yohimbine can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Yohimbine is combined with Nimesulide.]
[C09AA04, perindopril, Yohimbine may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Yohimbine may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, Yohimbine may decrease the antihypertensive activities of Hydrochlorothiazide.]
[R05DA03, hydrocodone, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, Yohimbine may decrease the antihypertensive activities of Hydroflumethiazide.]
[G04BD06, propiverine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The metabolism of Yohimbine can be decreased when combined with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Yohimbine is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Yohimbine.]
[C02AC06, rilmenidine, Yohimbine may decrease the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Ibuprofen is combined with Yohimbine.]
[L01DB06, idarubicin, The metabolism of Yohimbine can be decreased when combined with Idarubicin.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Yohimbine.]
[N06AA02, imipramine, The serum concentration of Yohimbine can be increased when it is combined with Imipramine.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Yohimbine.]
[C03BA11, indapamide, Yohimbine may decrease the antihypertensive activities of Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Yohimbine.]
[C02CA02, indoramin, Yohimbine may decrease the antihypertensive activities of Indoramin.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Yohimbine is combined with Milnacipran.]
[A03AA30, piperidolate, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Articaine.]
[N05BA12, alprazolam, The therapeutic efficacy of Alprazolam can be increased when used in combination with Yohimbine.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Yohimbine.]
[R06AE01, buclizine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Yohimbine can be decreased when combined with Cerivastatin.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Yohimbine.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Yohimbine.]
[N06AA13, iprindole, The serum concentration of Yohimbine can be increased when it is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Yohimbine is combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Yohimbine.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Isoetharine is combined with Yohimbine.]
[C09AA16, imidapril, Yohimbine may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Yohimbine.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Yohimbine.]
[J04AC01, isoniazid, The metabolism of Yohimbine can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, The risk or severity of hypertension can be increased when Isoprenaline is combined with Yohimbine.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Yohimbine is combined with Isoxsuprine.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Yohimbine.]
[L04AC07, tocilizumab, The metabolism of Yohimbine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Yohimbine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Yohimbine is combined with Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Yohimbine can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Yohimbine can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Ketoprofen is combined with Yohimbine.]
[L04AA24, abatacept, The metabolism of Yohimbine can be increased when combined with Abatacept.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Arbutamine is combined with Yohimbine.]
[N04BC09, rotigotine, Yohimbine may increase the sedative activities of Rotigotine.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Yohimbine is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The metabolism of Yohimbine can be decreased when combined with Labetalol.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Yohimbine.]
[C02AA05, deserpidine, Yohimbine may decrease the antihypertensive activities of Deserpidine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Yohimbine is combined with Lacosamide.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Levodopa is combined with Yohimbine.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Yohimbine.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Yohimbine.]
[N06AA07, lofepramine, The serum concentration of Yohimbine can be increased when it is combined with Lofepramine.]
[N05BA06, lorazepam, The therapeutic efficacy of Lorazepam can be increased when used in combination with Yohimbine.]
[C10AA02, lovastatin, The metabolism of Yohimbine can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Yohimbine.]
[L01EG01, temsirolimus, The metabolism of Yohimbine can be decreased when combined with Temsirolimus.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Yohimbine can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Yohimbine can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Yohimbine.]
[C02BB01, mecamylamine, Yohimbine may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Yohimbine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Yohimbine.]
[N05BA03, medazepam, The therapeutic efficacy of Medazepam can be increased when used in combination with Yohimbine.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Yohimbine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Yohimbine.]
[C01CA11, mephentermine, The therapeutic efficacy of Yohimbine can be decreased when used in combination with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Yohimbine.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Yohimbine.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Yohimbine.]
[N05BC01, meprobamate, The therapeutic efficacy of Meprobamate can be increased when used in combination with Yohimbine.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Yohimbine is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Yohimbine.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Paliperidone is combined with Yohimbine.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Metaraminol is combined with Yohimbine.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Yohimbine.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Yohimbine.]
[N06BA03, methamphetamine, The therapeutic efficacy of Yohimbine can be decreased when used in combination with Metamfetamine.]
[A03AB07, methantheline, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Yohimbine is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Yohimbine is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Yohimbine.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Yohimbine is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Yohimbine can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Yohimbine.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Yohimbine.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Yohimbine is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Methoxamine is combined with Yohimbine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Yohimbine.]
[C02AB01, methyldopa, Yohimbine may decrease the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, Yohimbine may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Yohimbine.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Yohimbine.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Yohimbine.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Yohimbine.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Yohimbine.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Yohimbine.]
[C03BA08, metolazone, Yohimbine may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, The metabolism of Yohimbine can be decreased when combined with Metoprolol.]
[C01BB02, mexiletine, The metabolism of Yohimbine can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Yohimbine is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Yohimbine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Yohimbine is combined with Aminophenazone.]
[N05CD08, midazolam, The therapeutic efficacy of Midazolam can be increased when used in combination with Yohimbine.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Yohimbine.]
[G03XB01, mifepristone, The metabolism of Yohimbine can be decreased when combined with Mifepristone.]
[C09CA03, valsartan, Yohimbine may decrease the antihypertensive activities of Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Yohimbine.]
[D11AX01, minoxidil, Yohimbine may decrease the antihypertensive activities of Minoxidil.]
[L01XX23, mitotane, The metabolism of Yohimbine can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Yohimbine can be decreased when used in combination with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Yohimbine is combined with Molindone.]
[C01BD01, amiodarone, The metabolism of Yohimbine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The serum concentration of Yohimbine can be increased when it is combined with Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Yohimbine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Yohimbine.]
[L04AB05, certolizumab pegol, The metabolism of Yohimbine can be increased when combined with Certolizumab pegol.]
[L01EX03, pazopanib, The metabolism of Yohimbine can be decreased when combined with Pazopanib.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Yohimbine.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Yohimbine.]
[N06AA17, amoxapine, The serum concentration of Yohimbine can be increased when it is combined with Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Yohimbine can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, Yohimbine may decrease the antihypertensive activities of Nadolol.]
[N04BC04, ropinirole, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Yohimbine.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Yohimbine is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Yohimbine.]
[V03AB15, naloxone, The metabolism of Yohimbine can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Yohimbine.]
[L04AC03, anakinra, The metabolism of Yohimbine can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Yohimbine is combined with Naphazoline.]
[N06BA01, amphetamine, The therapeutic efficacy of Yohimbine can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Naproxen is combined with Yohimbine.]
[N06AX21, duloxetine, The metabolism of Yohimbine can be decreased when combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Yohimbine.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Yohimbine.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Yohimbine is combined with Iloperidone.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Yohimbine may decrease the antihypertensive activities of Telmisartan.]
[C10AD02, niacin, The metabolism of Yohimbine can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Yohimbine is combined with Nialamide.]
[C08CA04, nicardipine, The metabolism of Yohimbine can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The risk or severity of hypertension can be increased when Nicergoline is combined with Yohimbine.]
[C08CA05, nifedipine, The metabolism of Yohimbine can be decreased when combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Yohimbine is combined with Niflumic acid.]
[C08CA06, nimodipine, Yohimbine may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Yohimbine may decrease the antihypertensive activities of Nisoldipine.]
[N05CD02, nitrazepam, The therapeutic efficacy of Nitrazepam can be increased when used in combination with Yohimbine.]
[C08CA08, nitrendipine, Yohimbine may decrease the antihypertensive activities of Nitrendipine.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Yohimbine.]
[N04BC05, pramipexole, The therapeutic efficacy of Pramipexole can be decreased when used in combination with Yohimbine.]
[C02DD01, nitroprusside, Yohimbine may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Yohimbine is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Nomifensine.]
[C01CA03, norepinephrine, Yohimbine may decrease the hypertensive activities of Norepinephrine.]
[C02KX01, bosentan, Yohimbine may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, The serum concentration of Yohimbine can be increased when it is combined with Nortriptyline.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Yohimbine is combined with Nylidrin.]
[L04AC04, rilonacept, The metabolism of Yohimbine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Yohimbine can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The serum concentration of Yohimbine can be increased when it is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Yohimbine is combined with Opium.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Orciprenaline is combined with Yohimbine.]
[G02CB04, quinagolide, The therapeutic efficacy of Quinagolide can be decreased when used in combination with Yohimbine.]
[G04CA02, tamsulosin, The metabolism of Yohimbine can be decreased when combined with Tamsulosin.]
[P02BA02, oxamniquine, The metabolism of Yohimbine can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, The therapeutic efficacy of Oxazepam can be increased when used in combination with Yohimbine.]
[C07AA02, oxprenolol, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Yohimbine.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Yohimbine.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Yohimbine is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Oxymetazoline is combined with Yohimbine.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Oxymorphone is combined with Yohimbine.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Yohimbine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Yohimbine.]
[M03AC01, pancuronium, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[N05CC05, paraldehyde, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Yohimbine is combined with Pargyline.]
[G04BD11, fesoterodine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Penbutolol is combined with Yohimbine.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Yohimbine is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Yohimbine.]
[N05CA01, pentobarbital, The metabolism of Yohimbine can be increased when combined with Pentobarbital.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Pergolide is combined with Yohimbine.]
[C08EX02, perhexiline, The metabolism of Yohimbine can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Yohimbine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Yohimbine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Yohimbine.]
[A10BA01, phenformin, The metabolism of Yohimbine can be decreased when combined with Phenformin.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Yohimbine is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Yohimbine can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, Yohimbine may decrease the antihypertensive activities of Phenoxybenzamine.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Yohimbine is combined with Phenprocoumon.]
[A08AA01, phentermine, The therapeutic efficacy of Yohimbine can be decreased when used in combination with Phentermine.]
[V03AB36, phentolamine, Yohimbine may decrease the antihypertensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Phenylbutazone is combined with Yohimbine.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Phenylephrine is combined with Yohimbine.]
[R01BA01, phenylpropanolamine, The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Yohimbine.]
[N03AB02, phenytoin, The metabolism of Yohimbine can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Yohimbine can be increased when combined with Golimumab.]
[C08CX01, mibefradil, The metabolism of Yohimbine can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Yohimbine.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Yohimbine.]
[J05AE01, saquinavir, The metabolism of Yohimbine can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Yohimbine can be decreased when combined with Piperazine.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Pipotiazine.]
[C09CA02, eprosartan, Yohimbine may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N04BC08, piribedil, The therapeutic efficacy of Piribedil can be decreased when used in combination with Yohimbine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Yohimbine is combined with Piritramide.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Yohimbine.]
[N02CX01, pizotyline, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Yohimbine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, Yohimbine may decrease the antihypertensive activities of Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Yohimbine is combined with Proxibarbal.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Yohimbine.]
[L04AC08, canakinumab, The metabolism of Yohimbine can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Yohimbine may decrease the antihypertensive activities of Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Yohimbine can be increased when it is combined with Ritonavir.]
[C07AB01, practolol, Yohimbine may decrease the antihypertensive activities of Practolol.]
[N05BA11, prazepam, The therapeutic efficacy of Prazepam can be increased when used in combination with Yohimbine.]
[C02CA01, prazosin, Yohimbine may decrease the antihypertensive activities of Prazosin.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Yohimbine.]
[P01BA03, primaquine, The metabolism of Yohimbine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Yohimbine can be increased when combined with Primidone.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Yohimbine.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Yohimbine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Yohimbine.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Yohimbine.]
[N04AA04, procyclidine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Yohimbine can be decreased when combined with Progesterone.]
[N05AA03, promazine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The metabolism of Yohimbine can be decreased when combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Yohimbine is combined with Propanidid.]
[A03AB05, propantheline, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Periciazine.]
[N05CM06, propiomazine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Yohimbine.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Yohimbine.]
[C07AA05, propranolol, Yohimbine may decrease the antihypertensive activities of Propranolol.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Yohimbine.]
[B01AC09, epoprostenol, Yohimbine may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, The serum concentration of Yohimbine can be increased when it is combined with Protriptyline.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Yohimbine can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Yohimbine.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Yohimbine is combined with Vinbarbital.]
[N05BB02, captodiamine, The therapeutic efficacy of Captodiame can be increased when used in combination with Yohimbine.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Yohimbine is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Yohimbine is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Mepyramine.]
[C01BA01, quinidine, The metabolism of Yohimbine can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Yohimbine can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Yohimbine can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, Yohimbine may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Yohimbine.]
[J04AB02, rifampin, The metabolism of Yohimbine can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Yohimbine is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Ritodrine is combined with Yohimbine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Yohimbine is combined with Oxitriptan.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Yohimbine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Yohimbine.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Salicylic acid is combined with Yohimbine.]
[S01FA02, scopolamine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Yohimbine.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Selegiline is combined with Yohimbine.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Yohimbine.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Yohimbine.]
[R03BB01, ipratropium bromide, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
